Stay updated on Ruxolitinib vs BAT in Chronic GvHD Clinical Trial
Sign up to get notified when there's something new on the Ruxolitinib vs BAT in Chronic GvHD Clinical Trial page.

Latest updates to the Ruxolitinib vs BAT in Chronic GvHD Clinical Trial page
- Check3 days agoChange DetectedThe page now shows a new Revision: v3.7.0 tag, replacing the previous Revision: v3.6.6, indicating the content was updated to a newer version.SummaryDifference0.0%

- Check10 days agoNo Change Detected
- Check17 days agoChange DetectedThe page revision tag was updated from v3.6.5 to v3.6.6, signaling deployment of a new build rather than content changes.SummaryDifference0.0%

- Check24 days agoChange DetectedA new NIH grant/contract identifier was added to the study's identifiers, indicating NIH funding/contract support for the REACH3 trial.SummaryDifference0.0%

- Check38 days agoChange DetectedThe page now records revision v3.6.5, replacing the previous v3.6.4. This indicates a small maintenance update rather than a substantive change to page content.SummaryDifference0.0%

- Check59 days agoChange DetectedRevision tag on the page updated from v3.6.3 to v3.6.4, indicating a new release of the page's content-management or rendering logic.SummaryDifference0.0%

- Check81 days agoChange DetectedRevision: v3.6.3 replaces v3.6.1 on the page, signaling a software update to the site. The study content and data remain unchanged as a result of this update.SummaryDifference0.0%

Stay in the know with updates to Ruxolitinib vs BAT in Chronic GvHD Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Ruxolitinib vs BAT in Chronic GvHD Clinical Trial page.